First Header Logo Second Header Logo

Connection

Roy Hantgan to Fibrinogens, Abnormal

This is a "connection" page, showing publications Roy Hantgan has written about Fibrinogens, Abnormal.
Connection Strength

0.154
  1. Lounes KC, Lefkowitz JB, Henschen-Edman AH, Coates AI, Hantgan RR, Lord ST. The impaired polymerization of fibrinogen Longmont (Bbeta166Arg-->Cys) is not improved by removal of disulfide-linked dimers from a mixture of dimers and cysteine-linked monomers. Blood. 2001 Aug 01; 98(3):661-6.
    View in: PubMed
    Score: 0.044
  2. Lounes KC, Lefkowitz JB, Coates AI, Hantgan RR, Henschen-Edman A, Lord ST. Fibrinogen Longmont. A heterozygous abnormal fibrinogen with B beta Arg-166 to Cys substitution associated with defective fibrin polymerization. Ann N Y Acad Sci. 2001; 936:129-32.
    View in: PubMed
    Score: 0.042
  3. Hogan KA, Gorkun OV, Lounes KC, Coates AI, Weisel JW, Hantgan RR, Lord ST. Recombinant fibrinogen Vlissingen/Frankfurt IV. The deletion of residues 319 and 320 from the gamma chain of firbinogen alters calcium binding, fibrin polymerization, cross-linking, and platelet aggregation. J Biol Chem. 2000 Jun 09; 275(23):17778-85.
    View in: PubMed
    Score: 0.041
  4. Webb CD, Hantgan RR, Byeff PD, Owen J. Fibrinogen New Britain: characterization of an A alpha Arg 16-->His variant human fibrinogen. Blood Coagul Fibrinolysis. 1994 Apr; 5(2):233-8.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.